Smallpox Medical Countermeasures Product Sales Increased 437%

Emergent BioSolutions Inc. reported financial results for the third quarter ended September 30, 2024. The Company's press release disclosed that Third-Quarter 2024 total revenues were $293.8 million, an increase of 9% compared to the prior year.

And that revenues from Smallpox Medical Countermeasures (MCM) products increased 437% compared with Q3 2023. 

Smallpox MCM revenues were $108.0 million from ACAM2000®, VIGIV, and TEMBEXA® product transactions. The revenue increase was primarily due to the timing of U.S. government purchases of ACAM2000® and VIGIV.

The U.S. Department of Health and Human Services awarded Emergent a contract in September 2019 valued at approximately $2 billion over ten years for the continued supply of ACAM2000 into the U.S. Strategic National Stockpile.

"Through disciplined execution and steady, measurable progress, Emergent's financial position is the strongest it has been since 2021, as evidenced by our favorable third-quarter results," stated CEO Joe Papa on November 6, 2024.

ACAM2000 is a second-generation live vaccinia virus, cell-cultured, replication-competent, single-dose vaccine that protects people against mpox and smallpox diseases. 

The World Health Organization (WHO) published 'Vaccines and Immunization for mpox: Interim Guidance, as did the U.S. Centers for Disease Control and Prevention, which expanded access via the Investigational New Drug Protocol, allowing ACAM2000 use to prevent mpox on June 30, 2022. 

In August 2024, the WHO declared the increasing number of mpox cases reported in the African Region a Public Health Emergency of International Concern.